Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

International Hepatology

Home » International Hepatology » Page 8
AASLD Featured New Voices | Terry Yip and Jimmy Lai Explore the New Progress of Liver Disease

AASLD Featured New Voices | Terry Yip and Jimmy Lai Explore the New Progress of Liver Disease

Posted by By Mourabit Halima 2024.12.05
Editor's note: At the recent AASLD 2024, the annual meeting of the American Association for the Study of Liver Diseases, top experts from the global liver disease field gathered to…
Read More
AASLD 2024丨Weight-Loss Surgery vs. Medication: A 5-Year Mortality Comparison in MAFLD Patients

AASLD 2024丨Weight-Loss Surgery vs. Medication: A 5-Year Mortality Comparison in MAFLD Patients

Posted by By Peng Longmei 2024.12.04
The rising mortality rate among patients with metabolic dysfunction-associated fatty liver disease (MAFLD) underscores the need for effective interventions. At the 2024 AASLD Annual Meeting, Dr. Leith Ghani from the…
Read More
AASLD 2024丨Dr. Qing Xie’s Team: TMF Improves Efficacy and Safety in ALT-Normal Chronic HBV Patients—Midterm Results from the PROMOTE Study

AASLD 2024丨Dr. Qing Xie’s Team: TMF Improves Efficacy and Safety in ALT-Normal Chronic HBV Patients—Midterm Results from the PROMOTE Study

Posted by By Mourabit Halima 2024.12.04
At the 2024 AASLD Annual Meeting, Dr. Qing Xie's team from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented findings on the efficacy and safety of a novel…
Read More
Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy

Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy

Posted by By Qingyuan Liu 2024.12.03
Chronic Hepatitis B (CHB) is a prevalent chronic inflammatory liver disease in China, often resulting in sustained hepatic parenchymal damage, liver fibrosis, and adverse outcomes such as cirrhosis, liver failure,…
Read More
AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

Posted by By El Bachir MOURABIT 2024.12.03
From November 15-19, 2024, the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in San Diego, USA. At this prestigious event, Dr.…
Read More
AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B

AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B

Posted by By Mourabit Halima 2024.12.03
Editor's note: Chronic hepatitis B (CHB) is a major public health problem worldwide. Although traditional antiviral drugs can inhibit viral replication to some extent, they are still inadequate in achieving…
Read More
AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

Posted by By El Bachir MOURABIT 2024.12.02
Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment…
Read More
AASLD 2024丨Dr. Qing Xie ‘s Team: Digital Precision Screening and Risk Stratification Improve Early Detection of Liver Cancer in China

AASLD 2024丨Dr. Qing Xie ‘s Team: Digital Precision Screening and Risk Stratification Improve Early Detection of Liver Cancer in China

Posted by By Mourabit Halima 2024.11.29
Liver cancer poses a significant public health challenge in China, with approximately 367,700 new cases in 2022, accounting for 42.5% of global incidence. However, the five-year survival rate is a…
Read More
Chinese Contributions at AASLD 2024: Dr. Yanyan Yu and Dr. Jinghang Xu’s Team Reveal Clinical Features and Prognostic Factors of HBV-Associated Glomer

Chinese Contributions at AASLD 2024: Dr. Yanyan Yu and Dr. Jinghang Xu’s Team Reveal Clinical Features and Prognostic Factors of HBV-Associated Glomer

Posted by By El Bachir MOURABIT 2024.11.26
At the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, two significant studies by Dr.  Yanyan Yu and Dr. Jinghang Xu from Peking University First Hospital…
Read More
Chinese Expertise at AASLD 2024: Dr. Qin Ning’s Team Achieves New Breakthroughs in CHB Clinical Cure Strategies

Chinese Expertise at AASLD 2024: Dr. Qin Ning’s Team Achieves New Breakthroughs in CHB Clinical Cure Strategies

Posted by By Mourabit Halima 2024.11.25
At the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, two landmark studies from Dr. Qin Ning’s team at Tongji Hospital, Huazhong University of Science and…
Read More

Posts pagination

Previous page 1 … 6 7 8 9 10 … 20 Next page
Recent Posts
  • ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy
  • CSCO 2025 │ Professor Lili Mao: Updates to Perioperative Therapy in the 2025 CSCO Melanoma Guidelines
  • Professor Haibo Wang: Advancing Comprehensive Breast Cancer Care through Innovation and Multidisciplinary Collaboration
  • “Those Who Fail to See the Whole Cannot Govern the Parts” — Professor Qiang Liu Shares New Perspectives on Neoadjuvant Therapy for Breast Cancer
  • CSCO Journey │ Professor Man Li: CSCO Member No. 168, Witness to China’s Leap Forward in Clinical Oncology
Recent Comments
    Archives
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top